Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy

International Journal of Cancer

Volumn 123, Issue 9, 2008, Pages 2120-2129

  Naschberger, Elisabeth ^a   Croner, Roland S ^a   Merkel, Susanne ^a   Dimmler, Arno ^a   Tripal, Philipp ^a   Amann, Kerstin U ^a   Kremmer, Elisabeth ^b   Brueckl, Wolfgang M ^a   Papadopoulos, Thomas ^a   Hohenadl, Christine ^c   Hohenberger, Werner ^a   Stürzl, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Angiogenesis; Colorectal carcinoma; Guanylate binding protein 1; Inflammation; Interferon

Indexed keywords

ANGIOGENESIS INHIBITOR; BINDING PROTEIN; BIOLOGICAL MARKER; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANYLATE BINDING PROTEIN 1; TRANSCRIPTOME; UNCLASSIFIED DRUG; CXCL10 PROTEIN, HUMAN; GBP1 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE INDUCTION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TH1 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY; CANCER STAGING; COLORECTAL TUMOR; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RETROSPECTIVE STUDY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHEMOKINE CXCL10; COLORECTAL NEOPLASMS; FEMALE; GTP-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TH1 CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 51649095449     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23764     Document Type: Article

References (64)

1. Steward BW, Kleinhues P, eds. Colorectal cancer. Lyon: IARC Press, 2003.
2. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 2007;8:439-43.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
4. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
6. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
9. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004; 126:1634-48.
10. Krok KL, Lichtenstein GR. Colorectal cancer in inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:43-8.
11. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoterin cancer induction. Semin Cancer Biol 2004;14:433-9.
12. Ray PS, Fox PL. A post-transcriptional pathway represses monocyte VEGF-A expression and angiogenic activity. EMBO J 2007;26:3360-72.
13. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000;12: 677-86.
14. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001;166:2276-82.
15. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37.
16. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
17. Pardoll D. T cells and tumours. Nature 2001;411:1010-12.
18. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
20. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007;67:1883-6.
21. Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Peru U, Dolman CS, Gillies SD, Reisfeld RA. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001;61: 8498-503.
22. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51.
23. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67:3396-405.
24. Prakash B, Praefcke GJ, Renault L, Wittinghofer A, Herrmann C. Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins. Nature 2000;403:567-71.
25. Ghosh A, Praefcke GJ, Renault L, Wittinghofer A, Herrmann C. How guanylate-binding proteins achieve assembly-stimulated processive cleavage of GTP to GMP. Nature 2006;440:101-4.
26. Naschberger E, Werner T, Vicente AB, Guenzi E, Töpolt K, Leubert R, Lubeseder-Martellato C, Nelson PJ, Stürzl M. Nuclear factor-κB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. Biochem J 2004;379:409-20.
27. Tripal P, Bauer M, Naschberger E, Mörtinger T, Hohenadl C, Cornali E, Thurau M, Stürzl M. Unique features of different members of the human guanylate-binding protein family. J Interferon Cytokine Res 2007;27:44-52.
28. Lubeseder-Martellato C, Guenzi E, Jörg A, Töpolt K, Naschberger E, Kremmer E, Zietz C, Tschachler E, Hutzler P, Schwemmle M, Matzen K, Grimm T, et al. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol 2002;161:1749-59.
29. Guenzi E, Töpolt K, Comali E, Lubeseder-Martellato C, Jörg A, Matzen K, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Barillari G, et al. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J 2001;20:5568-77.
30. Guenzi E, Töpolt K, Lubeseder-Martellato C, Jörg A, Naschberger E, Benelli R, Albini A, Stürzl M. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J 2003;22: 3772-82.
31. Naschberger E, Lubeseder-Martellato C, Meyer N, Gessner R, Kremmer E, Gessner A, Stürzl M. Human guanylate binding protein-1 is a secreted GTPase present in increased concentrations in the cerebrospinal fluid of patients with bacterial meningitis. Am J Pathol 2006;169:1088-99.
32. Sobin LH, Wittekind C, eds. UICC, 6th ed. New York: Wiley, 2002.
33. Jass JR, Sobin LH. Histological classification of tumoursed. Berlin: Springer, 1989.
34. Soreide O, Norstein J, Fielding LP, Silen W. International standardization and documentation of the treatment of rectal cancer. Berlin: Springer, 1997.
35. Chalmers CR, Fenwick SW, Toogood GJ, Hull MA. Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. Angiogenesis 2006;9:193-200.
36. Stürzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G, Biberfeld P, Monini P, Browning PJ, Ensoli B. Expression of K13/V-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1999;91:1725-33.
37. Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 1992;89:7046-50.
38. Croner RS, Peters A, Brueckl WM, Matzel KE, Klein-Hitpass L, Brabletz T, Papadopoulos T, Hohenberger W, Reingruber B, Lausen B. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 2005;104:395-404.
39. Croner RS, Foertsch T, Brueckl WM, Guenther K, Siebenhaar R, Stremmel C, Matzel KE, Papadopoulos T, Kirchner T, Behrens J, Klein-Hitpass L, Stuerzl M, et al. Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis 2005;20:353-62.
40. Croner RS, Guenther K, Foertsch T, Siebenhaar R, Brueckl WM, Stremmel C, Hlubek F, Hohenberger W, Reingruber B. Tissue preparation for gene expression profiling of colorectal carcinoma: three alternatives to laser microdissection with preamplification. J Lab Clin Med 2004;143:344-51.
41. Greenwood M. The natural duration of cancer. Rep Publ Hlth Med Subj 1926;33:1-26.
42. Krebs in Deutschlanded. Saarbrücken: Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI, 2006.
43. Inciardi JF, Lee JG, Stijnen T. Incidence trends for colorectal cancer in California: implications for current screening practices. Am J Med 2000;109:277-81.
44. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005;16:593-609.
45. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004;25:201-9.
46. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10. Mig, and, I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-49.
47. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004;173: 6234-40.
48. Mehrle S, Schmidt J, Buchler MW, Watzl C, Marten A. Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP. Mol Immunol 2008;45:796-804.
49. Bhat R, Eissmann P, Endt J, Hoffmann S, Watzl C. Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol 2006; 79:417-24.
50. Partida-Sanchez S, Goodrich S, Kusser K, Oppenheimer N, Randall TD, Lund FE. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 2004;20:279-91.
51. Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, Odashiro K, Nobuyoshi M, Hori M, Nakamura Y, Tanaka T. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 2004;429:72-5.
52. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ, Jr, Krook JE, Mailliard JA, Gerstner JB, Pazdur R. Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995;13: 2324-9.
53. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
54. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007;13:498-507.
55. Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Florholmen J. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 2007;56:985-95.
56. Kammertoens T, Schuler T, Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 2005;11:225-31.
57. Ferm M, Gronberg A, Tally M. IFN-gamma treatment increases insulin binding and MHC class I expression in erythroleukemia cells. Immunol Invest 1996;25:37-47.
58. Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-γ. TGF-beta, and cell density. J Immunol 2007;179:1549-58.
59. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, et al. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
60. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-γ in situ. Cancer Sci 2006;97:57-63.
61. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004;14:195-200.
62. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997;89:2635-43.
63. Shao X, Liu C. Influence of IFN-α and IFN-γ on lymphangiogenesis. J Interferon Cytokine Res 2006;26:568-74.
64. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78.